Overview

Effects of Kuvan on Melatonin Secretion

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study examines the effect of tetrahydrobiopterin (Kuvan) and Large Neutral Amino Acid (LNAA) therapy on melatonin and dopamine levels in individuals with Phenylketonuria (PKU). The investigators hypothesize that Kuvan therapy will improve melatonin secretion and urine dopamine levels to some extent. However significantly greater responses in melatonin and dopamine secretions may be observed with combined treatment with Kuvan and supplementation of LNAA.
Phase:
Phase 4
Details
Lead Sponsor:
University of Southern California
Collaborator:
BioMarin Pharmaceutical
Treatments:
Melatonin
Serotonin